Astrazeneca: Swot Analysis

1755 Words8 Pages
SWOT Analysis Strengths Interestingly, the company claims that its core strength is derived from its outstanding portfolio of products, its global reach and, above all, the creativity and commitment of its employees. It has ten products each with global sales of over $1 billion i.e. products such as Nexium, Seroquel, Crestor, Arimidex and Symbicort (2005). The global reach of the company is also becoming strong, as it is starting to show signs of success in China, growing their business there by over 200% over the past five years. Strong growth is also being achieved in other Asian countries, in Latin America and in Eastern Europe ( 2005). Aside from its reach, the company is a member of the Pharmaceutical Research…show more content…
AstraZeneca officials would not discuss the odds of cutting a deal with generic makers to market an "authorized" generic Toprol, which might mitigate the revenue loss (Ginsberg, 2006ba). Opportunities In terms of opportunities, the company has many to be glad about. First, its recent success in countries such as China, Latin America, and Eastern Europe can open up many possibilities. Another opportunity for the company is the increasing need for innovative drugs, especially on diseases that are currently difficult to cure such as cancer and diabetes. The company has the potential to create breakthrough drugs as shown in their development of Galida and Crestor. Improvements and innovations in oncology medications is also one of the brewing opportunities for the company. Alliances were made by the company to strengthen their capability in R&D in that field. In 2003, it has entered into alliance with Abgenix for broad collaboration, license and investment alliance to discover, develop and commercialize fully human monoclonal antibodies to treat cancer. This alliance also includes co-development component under which Abgenix will generate additional antibody product candidates that AstraZeneca will have the option to co-develop with Abgenix ( 2003). The companies will share development costs and responsibilities for any co-development candidates selected (2003). Astrazeneca also made a licensing and collaboration
Open Document